arrow
J

Justin T. Jordan

Harvard University
H指数:34
被引数:5,176

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
2025-12-150
PRE
Prognostic significance of contrast enhancement in newly diagnosed grade 2IDH-mutant glioma

对比增强在 newly diagnosed grade 2 IDH-mutant glioma 中的预后意义

2025-11-010
PRE
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma

同步系统性及中枢神经系统弥漫大B细胞淋巴瘤的治疗与预后回顾性研究

2025-11-010
OAAI
SCHWANNOMAS DISPLAY CONSERVED CELLULAR STATES AND PREFERENTIAL MHC CLASS II ANTIGEN PRESENTATION ACROSS DIFFERENT GENETIC BACKGROUNDS AND ANATOMIC LOCATIONS

神经鞘瘤表现出保守的细胞状态,并在不同的遗传背景和解剖位置上表现出对MHC II类抗原的优先呈递。

2025-10-010
OA
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes

伊沃西尼布治疗IDH1-mutant胶质瘤,2-4级: 耐受性,反应预测因子和结果

2024-12-191
OAAI
EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

PAXALISIB在新诊断和复发胶质母细胞瘤的GBM敏捷3期注册平台试验中的评估

2024-11-110
PRE
REAL WORLD EXPERIENCE USING THE IDH INHIBITOR IVOSIDENIB IN IDH MUTANT GLIOMA: TOLERABILITY AND OUTCOMES
2024-11-110
PRE
Prescription Drug Prices
2024-03-120
PRE
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells

CD19-directed嵌合抗原受体T细胞过继免疫治疗后原发性和继发性中枢神经系统淋巴瘤的神经毒性和管理

2023-07-047
PRE